Jeremy S. Abramson

Also affiliated with Massachusetts General Hospital, Center for Cancer Research

MedicineSocial SciencesImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile

0.518Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL

Blood Advances(2024)10.1182/bloodadvances.2023011574

Top 37%

0.518DataRank

Top 37%12 citations

Danielle M. Brander, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Heather A. Walker +18 more

Papers

Driven by 26 papers — median percentile 63. Top paper: “Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma”.

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma

Journal of Clinical Oncology(2020)10.1200/jco.20.00303

N/A

5.0DataRank · unranked

152 citations

Kieron Dunleavy, Jeremy S. Abramson, Bayard L. Powell, Brian K. Link, Prapti A. Patel +19 more

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Blood(2020)10.1182/blood.2020006464

N/A

1.9DataRank · unranked

59 citations

Jason L. Weirather, Margaretha G.M. Roemer, Mikel Lipschitz, Alyssa Kelley, Pei-Hsuan Chen +26 more

Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network

The Oncologist(2022)10.1093/oncolo/oyac134

N/A

0.867DataRank · unranked

22 citations

Rebecca S. Heist, Adam Z. Bard, Annacarolina F L da Silva, Ibiayi Dagogo‐Jack, Valentina Nardi +45 more

Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines

JACC Heart Failure(2022)10.1016/j.jchf.2022.03.006

N/A

0.759DataRank · unranked

157 citations

Zsófia D. Drobni, Thiago Quinaglia Araujo Costa Silva, Amna Zafar, Jingyi Gong, Daniel A. Zlotoff +14 more

Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma

Blood(2022)10.1182/blood.2022016534

N/A

0.673DataRank · unranked

88 citations

Kostiantyn Dreval, Daniela S. Gerhard, Laura K. Hilton, Jeremy S. Abramson, Richard F. Ambinder +63 more

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

Blood(2025)10.1182/blood.2024025563

N/A

0.596DataRank · unranked

52 citations

Jacob Soumerai, Jeremy S. Abramson, Jeffrey A. Barnes, Philip Caron, Shalini Chhabra +23 more

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL

Blood Advances(2024)10.1182/bloodadvances.2023011574

Top 37%

0.518DataRank

Top 37%12 citations

Danielle M. Brander, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Heather A. Walker +18 more

EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential

Blood Advances(2022)10.1182/bloodadvances.2022008550

N/A

0.442DataRank · unranked

18 citations

Zijun Y. Xu‐Monette, Jeremy S. Abramson, Aliyah R. Sohani, Govind Bhagat, Alexandar Tzankov +20 more

CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7507

N/A

0.312DataRank · unranked

7 citations

Travis Dockter, Amy S. Ruppert, Lale Kostakoglu, Heiko Schöder, Eric D. Hsi +8 more

DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma

OncoImmunology(2024)10.1080/2162402x.2024.2384667

N/A

0.165DataRank · unranked

2 citations

Cancan Luo, Yu Li, Yong Li, Govind Bhagat, Alexandar Tzankov +26 more

Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R

Blood Advances(2023)10.1182/bloodadvances.2023010223

N/A

0DataRank · unranked

0 citations

Kieron Dunleavy, Jeremy S. Abramson, Brian K. Link, Bayard L. Powell, Christopher Melani +10 more

Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

Leukemia & lymphoma/Leukemia and lymphoma(2024)10.1080/10428194.2024.2310144

N/A

0DataRank · unranked

17 citations

Mark N Sorial, Uvette Lou, Michelle Yu, Andrea Y. Delgado Medrano, Josie Ford +4 more

BTK inhibitor–induced defects in human neutrophil effector activity against Aspergillus fumigatus are restored by TNF-α

JCI Insight(2024)10.1172/jci.insight.176162

N/A

0DataRank · unranked

11 citations

Olivia W. Hepworth, Kyle J. Basham, Patricia Simaku, Arianne J. Crossen, Kyle D. Timmer +13 more

Chronic lymphocytic leukemia patients with chromosome 6q deletion as the sole cytogenetic abnormality display a high frequency of RPS15 mutations and have a poor prognosis

American Journal of Hematology(2024)10.1002/ajh.27421

N/A

0DataRank · unranked

0 citations

Teresa González, Miguel Quijada Álamo, Gian Matteo Rigolin, Adrian M. Dubuc, Ángela Villaverde Ramiro +15 more

CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting

Transplantation and Cellular Therapy(2025)10.1016/j.jtct.2025.10.024

N/A

0DataRank · unranked

3 citations

Matthew A. Lunning, Mazyar Shadman, Sairah Ahmed, Jeremy S. Abramson, Miguel‐Angel Perales +14 more

DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features

Blood Cancer Discovery(2025)10.1158/2643-3230.bcd-24-0240

N/A

0DataRank · unranked

4 citations

Carlos A. García‐Prieto, Kostiantyn Dreval, Laura K. Hilton, Jeremy S. Abramson, Nancy L. Bartlett +34 more

Short-duration infusion obinutuzumab with venetoclax in chronic lymphocytic leukemia: a prospective observational study

Blood Neoplasia(2025)10.1016/j.bneo.2025.100075

N/A

0DataRank · unranked

1 citations

Matthew Lei, Robert Redd, Ruchi Rana, Uvette Lou, Mark N Sorial +19 more

Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma

Research Square(2025)10.21203/rs.3.rs-5732026/v1

N/A

0DataRank · unranked

0 citations

Wenyu Shi, Zijun Y. Xu‐Monette, Youchao Jia, Alexandar Tzankov, Heounjeong Go +37 more

414 | CT‐BASED BODY COMPOSITION IN PATIENTS WITH FOLLICULAR LYMPHOMA COMPARED WITH THE GENERAL POPULATION, AND ASSOCIATION BETWEEN BODY COMPOSITION AND LYMPHOMA OUTCOMES

Hematological Oncology(2025)10.1002/hon.70094_414

N/A

0DataRank · unranked

0 citations

Lea Mantz, Robert Redd, Matthew Lei, Jeremy S. Abramson, J. Barnes +14 more

142 | LISOCABTAGENE MARALEUCEL IN R/R FL (TRANSCEND FL): IMPACT OF PRIOR LINES OF THERAPY, BENDAMUSTINE EXPOSURE, AND DISEASE PROGRESSION ≤ 24 MONTHS OF INITIAL SYSTEMIC THERAPY

Hematological Oncology(2025)10.1002/hon.70093_142

N/A

0DataRank · unranked

0 citations

Juan Luis Reguera Ortega, Franck Morschhauser, Guillaume Cartron, Aaron P. Rapoport, Koji Izutsu +14 more

140 | PHASE 2 TRIAL OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN COMBINATION WITH ACALABRUTINIB IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMAS (LBCL)

Hematological Oncology(2025)10.1002/hon.70093_140

N/A

0DataRank · unranked

0 citations

Jon Arnason, Robert Redd, J. Erika Haydu, Jacob D. Soumerai, Jeffrey A. Barnes +7 more

Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma

Blood Cancer Journal(2025)10.1038/s41408-025-01323-8

N/A

0DataRank · unranked

0 citations

Zijun Y. Xu‐Monette, Youchao Jia, Alexandar Tzankov, Heounjeong Go, Ling Li +38 more

Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e20004

N/A

0DataRank · unranked

0 citations

Sumithra J. Mandrekar, Allison M. Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander +15 more

Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary

UNC Libraries(2020)10.17615/22pk-t926

N/A

0DataRank · unranked

0 citations

Shanxiang Zhang, Qing Ye, Attilio Orazi, Youli Zu, Jeremy S. Abramson +27 more

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

Blood(2023)10.1182/blood.2023021274

N/A

0DataRank · unranked

47 citations

Nicholas Lambert, Paolo F. Caimi, Mwanasha H. Merrill, Priyanka Pullarkat, Richard Godby +19 more

Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma

Blood Advances(2023)10.1182/bloodadvances.2023011793

N/A

0DataRank · unranked

16 citations

Tianzhou Yu, Jeremy S. Abramson, Mohamed Abou‐El‐Enein, Jee H. Choe

Jeremy S. Abramson

Indexed papers

Top data-sharing exemplar

Papers